Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RPC1063 Clear all

Conditions: Multiple Sclerosis
Interventions: RPC-1063; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 56
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 49 more

Conditions: Healthy Volunteer
Interventions: Ozanimod, Gemfibrozil, Itraconazole, Rifampin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Zeposia; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2041
U.S. locations: 1
States / cities: Lawrenceville, New Jersey

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Berkeley, California • Fresno, California • Sacramento, California + 3 more

Conditions: Healthy Volunteers
Interventions: ozanimod; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Healthy Volunteer
Interventions: Phenelzine, Tyramine, Phenelzine placebo, ozanimod placebo, ozanimod; Drug
Lead sponsor: Celgene; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Fatigue, Multiple Sclerosis
Interventions: Ozanimod; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Female only
Enrollment: 1,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Ulcerative Colitis
Interventions: RPC1063, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 113
States / cities: Sun City, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 87 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Female only
Enrollment: 1,182 participants
Timeline: 2022 – 2032
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Crohn's Disease
Interventions: RPC1063; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: Tucson, Arizona • Largo, Florida • Palmetto Bay, Florida + 10 more

Conditions: Crohn Disease
Interventions: Ozanimod, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 188
States / cities: Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 140 more

Conditions: Crohn Disease
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Garden Grove, California • Los Angeles, California • Sacramento, California + 15 more

Conditions: Multiple Sclerosis
Interventions: RPC1063; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Long Beach, California • San Francisco, California • Raleigh, North Carolina + 3 more

Conditions: Ulcerative Colitis
Interventions: RPC1063; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 10
States / cities: Tucson, Arizona • Anaheim, California • Mission Hills, California + 7 more

Conditions: Colitis, Ulcerative
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 85
States / cities: Dothan, Alabama • Chandler, Arizona • Gilbert, Arizona + 63 more

Conditions: Colitis, Ulcerative
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 36
States / cities: Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more

Conditions: Liver Diseases, Digestive System Diseases
Interventions: Ozanimod; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Multiple Sclerosis
Interventions: RPC1063; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2,494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 19
States / cities: Phoenix, Arizona • Berkeley, California • Fresno, California + 15 more

Conditions: Ulcerative Colitis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 73 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 10
States / cities: Anaheim, California • La Jolla, California • Oceanside, California + 7 more

Conditions: Lactating Women, Breastfed Infants
Interventions: Breast milk, plasma, and blood samples; Diagnostic Test
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Healthy Volunteers
Interventions: Placebo, Rasigiline, Phenelzine, Ozanimod; Other · Drug
Lead sponsor: Celgene; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy Volunteers
Interventions: Ozanimod; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

An Examination of Cognitive Fatigue Using Functional Neuroimaging

Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response

Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients

A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

A Lactation Study in Women Receiving Treatment With Ozanimod

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects